A team, led by senior author Morris J. Birnbaum, MD, PhD, the Willard and Rhoda Ware Professor of Medicine, with the Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, found that the diabetes drug metformin works in a different way than previously understood. Their research in mice found that metformin suppresses the liver hormone glucagon's ability to generate an important signaling molecule, pointing to new drug targets. The findings were published online this week in Nature.
For fifty years, one of the few classes of therapeutics effective in reducing the overactive glucose production associated with diabetes has been the biguanides, which includes metformin, the most frequently prescribed drug for type 2 diabetes. The inability of insulin to keep liver glucose output in check is a major factor in the high blood sugar of type 2 diabetes and other diseases of insulin resistance.
"Overall, metformin lowers blood glucose by decreasing liver production of glucose," says Birnbaum. "But we didn't really know how the drug accomplished that."
Despite metformin's success, its mechanism of action remained imperfectly understood. About a decade ago, researchers suggested that metformin reduces glucose synthesis by activating the enzyme AMPK. But this understanding was challenged by genetic experiments in 2010 by collaborators on the present Nature study. Coauthors Marc Foretz and Benoit Viollet from Inserm, CNRS, and Université Paris Descartes, Paris, found that the livers of mice without AMPK still responded to metformin, indicating that blood glucose levels were being controlled outside of the AMPK pathway.
Taking another look at how glucose is regulated normally, the team knew that when there is no food intake and glucose decreases, glucagon is secreted from the pancreas to signal the liver to produce glucose. They then asked if metformin works by stopping the glucagon cascade.
The Nature study describes a novel mechanism by which metformin antagonizes the action of glucagon, thus reducing fasting glucose levels. The team showed that metformin leads to the accumulation of AMP in mice, which inhibits an enzyme called adenylate cyclase, thereby reducing levels of cyclic AMP and protein kinase activity, eventually blocking glucagon-dependent glucose output from liver cells.
From this new understanding of metformin's action, Birnbaum and colleagues surmise that adenylate cyclase could be a new drug target by mimicking the way in which it is inhibited by metformin. This strategy would bypass metformin's affect on a cell's mitochondria to make energy, and possibility avoid the adverse side effects experienced by many people who take metformin, perhaps even working for those patients resistant to metformin.
University of Pennsylvania School of Medicine: http://www.uphs.upenn.edu/news/
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Understanding aggressive tumors in pets may lead to better treatments for the nastiest forms of the disease in people
Anti-GM activists will never accept anything ‘unnatural’, but the genetically modified potato being developed in Norwich could be of tremendous benefit
A new study is the first rigorous test of a controversial idea: that the everyday interactions between caregiver and child can change the way autism develops
Emergency crews who spent months clearing up after the attacks on the World Trade Center in New York have higher rates of rheumatoid arthritis and lupus
Six years ago, husband-and-wife scientists used gene therapy to cure colorblindness in monkeys. Now they're trying to make it work for the millions of people with faulty color vision.
Faced with unreliable screening, many women with a high lifetime risk of cancer opt for preventative surgery, just as Jolie did.
CAIRO (Reuters) - A team from a Spanish university has discovered what Egyptian authorities are calling the world's oldest evidence of breast cancer in the 4,200-year-old skeleton of an adult woman.
Early efforts to test legal marijuana are finding that it's got lots of buzzworthy THC. But it can also have fungus, chemical residue and bacteria. What that means for health and safety isn't clear.
Should the government recommend lean meat as part of a healthy diet? That's emerged as a political flashpoint. The panel working on federal guidelines says the evidence on lean meat is muddled.
A new coating makes ketchup slide out of the bottle and toothpaste slip out of a tube, right down to the last drop. So why not put the slick surface on an Ebola suit so the virus doesn't stick?